Australia Stock Exchange release from NEUREN PHARMACEU : Ethics approval for Angelman Phase 2 trial in Australia
10/03/2022 22:33
Australia Stock Exchange release from NEUREN PHARMACEU NEU.AX : Ethics approval for Angelman Phase 2 trial in Australia
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union